Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275570 | 0.87 | LMNA (0.35) | LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL10276050 | 0.75 | MEN1 (0.35) | LMNAMEN1KMT2A | |
| SCHEMBL10275520 | 0.73 | MEN1 (0.34) | LMNAMEN1KMT2A | |
| SCHEMBL10275523 | 0.73 | MEN1 (0.34) | LMNAMEN1KMT2A | |
| SCHEMBL10276061 | 0.72 | LMNA (0.37) | LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL10276267 | 0.69 | KDM1A (0.34) | — | |
| SCHEMBL10275810 | 0.69 | LMNA (0.37) | LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL10276064 | 0.68 | LMNA (0.35) | LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL10276404 | 0.66 | KDM1A (0.35) | — | |
| SCHEMBL10275579 | 0.64 | MEN1 (0.37) | LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | LMNA 1504/4885MEN1 4229/4885KMT2A 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.